The US Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals’ Lynozyfic ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron ...

Concerns about bribery allegations, angry CBS News staff and a looming high-stakes merger made for tense monthslong negotiations. The travel-review company's shares have fallen after it rejected ...

Stocks in the healthcare industry fell ahead of June's nonfarm payrolls, which economists surveyed by The Wall Street Journal expect to show declining job creation. Centene stock plummeted 40% after ...

This was the stock's third consecutive day of gains.

Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

IP litigation lawyers Joe Loy and Matt Hershkowitz discuss claim construction—one of the most important strategic decisions in patent litigation. The article delves into how various courts address ...

The global Ophthalmology Drugs Market , valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025 and is projected to advance at ...

Indian drugmaker Biocon has announced that Health Canada has granted a Notice of Compliance for Yesafili (aflibercept), a ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best S&P 500 stocks with huge upside potential. On June 24, ...

Westlake and Ascend close plants, Chemify opens AI-robotics lab, Formation licenses gusacitinib to Sanofi, and more ...